Alison Helen Reid
Papers
1
Total Citations
10
H-Index
1
About
Alison Helen Reid is a leading clinician-researcher in urologic oncology, with a focused expertise in the management of testicular cancer, particularly seminoma. Her major contribution lies in pioneering less toxic, minimally invasive treatment strategies for clinical stage IIa seminoma, challenging traditional multi-agent chemotherapy and radiotherapy protocols. Her most-cited work, a 2019 study on clinical outcomes of minimally invasive retroperitoneal lymph node dissection combined with single-dose carboplatin, has garnered 10 citations and represents a paradigm shift toward reducing long-term toxicity in young patients. This research directly addresses the significant short- and long-term side effects of standard cisplatin-based chemotherapy and paraaortic/pelvic radiation, offering a tailored, organ-sparing approach. Reid’s work is notable for its practical impact on clinical guidelines and patient quality of life, establishing her as a key voice in the movement toward de-escalation of therapy in germ cell tumors. Her achievements underscore a commitment to evidence-based, patient-centered innovation in a field where balancing cure with survivorship is paramount.
Research Focus
Key Achievements
Top Papers
- 1